123 related articles for article (PubMed ID: 25427845)
1. Comparison of two methods for assessing diabetes risk in a pharmacy setting in Australia.
Kilkenny MF; Johnson R; Andrew NE; Purvis T; Hicks A; Colagiuri S; Cadilhac DA
BMC Public Health; 2014 Nov; 14():1227. PubMed ID: 25427845
[TBL] [Abstract][Full Text] [Related]
2. Pharmacy Diabetes Screening Trial: protocol for a pragmatic cluster-randomised controlled trial to compare three screening methods for undiagnosed type 2 diabetes in Australian community pharmacy.
Krass I; Carter R; Mitchell B; Mohebbi M; Shih STF; Trinder P; Versace VL; Wilson F; Namara KM
BMJ Open; 2017 Dec; 7(12):e017725. PubMed ID: 29284715
[TBL] [Abstract][Full Text] [Related]
3. Pharmacy diabetes screening trial (PDST): Outcomes of a national clustered RCT comparing three screening methods for undiagnosed type 2 diabetes (T2DM) in community pharmacy.
Krass I; Carter R; Mitchell B; Mohebbi M; Shih STF; Trinder P; Versace VL; Wilson F; Mc Namara KP
Diabetes Res Clin Pract; 2023 Mar; 197():110566. PubMed ID: 36738834
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of men classified at high-risk for type 2 diabetes mellitus using the AUSDRISK screening tool.
Aguiar EJ; Morgan PJ; Collins CE; Plotnikoff RC; Callister R
Diabetes Res Clin Pract; 2015 Apr; 108(1):45-54. PubMed ID: 25707921
[TBL] [Abstract][Full Text] [Related]
5. Participant and GP perspectives and experiences of screening for undiagnosed type 2 diabetes in community pharmacy during the Pharmacy Diabetes Screening Trial.
Krass I; Twigg MJ; Mitchell B; Wilson F; Mohebbi M; Trinder P; Shih STF; Carter R; Versace VL; McNamara K
BMC Health Serv Res; 2023 Dec; 23(1):1337. PubMed ID: 38041094
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of AUSDRISK as a screening tool for lifestyle modification programs: international implications for policy and cost-effectiveness.
Malo JA; Versace VL; Janus ED; Laatikainen T; Peltonen M; Vartiainen E; Coates MJ; Dunbar JA
BMJ Open Diabetes Res Care; 2015; 3(1):e000125. PubMed ID: 26468399
[TBL] [Abstract][Full Text] [Related]
7. AUSDRISK - application in general practice.
Wong KC; Brown AM; Li SC
Aust Fam Physician; 2011 Jul; 40(7):524-6. PubMed ID: 21743862
[TBL] [Abstract][Full Text] [Related]
8. Assessment of diabetes knowledge, screening and uptake of community diabetes programs in a peri-urban region in Australia.
Osuagwu UL; Sharma S; Silva D; Saunders J; Pillay J; Piya MK; Simmons D
Diabetes Metab Syndr; 2021; 15(5):102257. PubMed ID: 34425557
[TBL] [Abstract][Full Text] [Related]
9. Arabic version of the Australian type 2 diabetes risk assessment tool (AUSDRISK): translation and validation.
Farag HFM; Sultan EA; Elrewany E; Abdel-Aziz BF
BMC Res Notes; 2022 Sep; 15(1):303. PubMed ID: 36138452
[TBL] [Abstract][Full Text] [Related]
10. Implementation of a mental health medication management intervention in Australian community pharmacies: Facilitators and challenges.
Hattingh HL; Kelly F; Fowler J; Wheeler AJ
Res Social Adm Pharm; 2017; 13(5):969-979. PubMed ID: 28583302
[TBL] [Abstract][Full Text] [Related]
11. Congruence between the Indian Diabetes Risk Score and Australian Type 2 Diabetes Risk Assessment tool screening in Asian-Indians.
Fernandez RS; Frost S
Nurse Res; 2013 Nov; 21(2):36-9. PubMed ID: 24171636
[TBL] [Abstract][Full Text] [Related]
12. Diabetes and cardiovascular disease risk screening model in community pharmacies in a developing primary healthcare system: a feasibility study.
Alzubaidi HT; Chandir S; Hasan S; McNamara K; Cox R; Krass I
BMJ Open; 2019 Nov; 9(11):e031246. PubMed ID: 31712336
[TBL] [Abstract][Full Text] [Related]
13. Opportunistic screening and health promotion for type 2 diabetes: an expanding public health role for the community pharmacist.
Dhippayom T; Fuangchan A; Tunpichart S; Chaiyakunapruk N
J Public Health (Oxf); 2013 Jun; 35(2):262-9. PubMed ID: 22976588
[TBL] [Abstract][Full Text] [Related]
14. Opportunistic Risk Screening for Type 2 Diabetes: Exploring of Application of Diabetes Risk Assessment Tool in Community Pharmacy in Australia and Thailand.
Thoopputra T; Pongmesa T; Newby DA; Schneider J; Li SC
Value Health Reg Issues; 2016 May; 9():1-7. PubMed ID: 27881250
[TBL] [Abstract][Full Text] [Related]
15. AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures.
Chen L; Magliano DJ; Balkau B; Colagiuri S; Zimmet PZ; Tonkin AM; Mitchell P; Phillips PJ; Shaw JE
Med J Aust; 2010 Feb; 192(4):197-202. PubMed ID: 20170456
[TBL] [Abstract][Full Text] [Related]
16. Pharmacy diabetes care program: analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy.
Krass I; Mitchell B; Clarke P; Brillant M; Dienaar R; Hughes J; Lau P; Peterson G; Stewart K; Taylor S; Wilkinson J; Armour C
Diabetes Res Clin Pract; 2007 Mar; 75(3):339-47. PubMed ID: 16884811
[TBL] [Abstract][Full Text] [Related]
17. Sequential screening for diabetes--evaluation of a campaign in Swiss community pharmacies.
Hersberger KE; Botomino A; Mancini M; Bruppacher R
Pharm World Sci; 2006 Jun; 28(3):171-9. PubMed ID: 17004016
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk screening program in Australian community pharmacies.
Peterson GM; Fitzmaurice KD; Kruup H; Jackson SL; Rasiah RL
Pharm World Sci; 2010 Jun; 32(3):373-80. PubMed ID: 20217476
[TBL] [Abstract][Full Text] [Related]
19. Risk assessment and HbA1c measurement in Norwegian community pharmacies to identify people with undiagnosed type 2 diabetes - A feasibility study.
Risøy AJ; Kjome RLS; Sandberg S; Sølvik UØ
PLoS One; 2018; 13(2):e0191316. PubMed ID: 29474501
[TBL] [Abstract][Full Text] [Related]
20. A model for assessment and referral of clients with bowel symptoms in community pharmacies.
Sriram D; McManus A; Emmerton LM; Parsons RW; Jiwa M
Curr Med Res Opin; 2016; 32(4):661-7. PubMed ID: 26700973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
